The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Naltrexone and Alcohol Dependence: Role of Subject Compliance
Abstract
BACKGROUND: Two previous double-blind, placebo-controlled studies demonstrated that naltrexone (50 mg/d) reduces alcohol drinking in alcohol-dependent subjects. In both studies, treatment compliance was excellent. However, a robust treatment effect size for naltrexone relative to placebo has been shown for compliant subjects but not for subjects who missed research visits. The goal of this study was to determine the effectiveness of naltrexone in subjects who received psychosocial treatment in a more naturalistic setting with respect to the role of treatment attendance and medication compliance. METHODS: Ninety-seven alcohol-dependent subjects were randomly assigned to receive either naltrexone (n = 48) or matching placebo (n = 49) for 12 weeks. All subjects received individual counseling (twice per week for the first month followed by once per week). RESULTS: Overall, naltrexone showed only modest effects in reducing alcohol drinking for the 12 weeks of treatment. However, naltrexone treatment efficacy improved across a variety of outcome measures for subjects who completed treatment and were highly compliant with taking medication. CONCLUSIONS: Naltrexone is clinically effective relative to placebo in individuals who comply with the treatment protocol and take medication. The modest treatment effects in the entire sample suggest that the clinical efficacy of naltrexone could be improved by enhancing treatment compliance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Hopkins Symptom Checklist (HSCL): A self-report symptom inventory
Derogatis, L. R., Lipman, R. S., Rickels, K., Uhlenhuth, E. H., & Covi, L. (1974) · Behavioral Science · doi:10.1002/bs.3830190102 · Cited by 4,604
Miller, R. G. (1981) · Cited by 3,336
Chi-Square Tests with One Degree of Freedom; Extensions of the Mantel-Haenszel Procedure
Mantel, N. (1963) · Journal of the American Statistical Association · doi:10.1080/01621459.1963.10500879 · Cited by 2,897
Naltrexone in the Treatment of Alcohol Dependence
Volpicelli, J. R. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110040006 · Cited by 1,828
Self-citationNaltrexone and Coping Skills Therapy for Alcohol Dependence: A Controlled Study
O'Malley, S. S. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110045007 · Cited by 1,487
Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised
Kobylski, T. P. (1988) · Psychosomatics · doi:10.1016/s0033-3182(88)72438-x · Cited by 1,054
How often is medication taken as prescribed? A novel assessment technique
Cramer, J. A. (1989) · JAMA · doi:10.1001/jama.261.22.3273 · Cited by 1,021
Alteration of ethanol self-administration by naltrexone
Altshuler, H. L., Phillips, P. E., & Feinhandler, D. A. (1980) · Life Sciences · doi:10.1016/0024-3205(80)90257-x · Cited by 397
Effect of naltrexone on alcohol “high” in alcoholics
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.4.613 · Cited by 308
Naloxone attenuates voluntary ethanol intake in rats selectively bred for high ethanol preference
Froehlich, J. C., Harts, J., Lumeng, L., & Li, T.-K. (1990) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(90)90174-g · Cited by 296
Cited by
Jonas, D. E., Amick, H. R., Feltner, C., Bobashev, G., Thomas, K., Wines, R., Kim, M. M., Shanahan, E., Gass, C. E., Rowe, C. J., et al. (2014) · JAMA · doi:10.1001/jama.2014.3628 · Cited by 923
Opioid antagonists for alcohol dependence
Srisurapanont, M., & Jarusuraisin, N. (2002) · The Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001867 · Cited by 764
Garbutt, J. C., Kranzler, H. R., O’Malley, S. S., Gastfriend, D. R., Pettinati, H. M., Silverman, B. L., Loewy, J. W., Ehrich, E. W., & Vivitrex Study Group, F. T. (2005) · JAMA · doi:10.1001/jama.293.13.1617 · Cited by 635
Naltrexone in the Treatment of Alcohol Dependence
Krystal, J. H., Cramer, J. A., Krol, W. F., Kirk, G. F., & Rosenheck, R. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011127 · Cited by 618
Carmen, B., Angeles, M., Ana, M., & María, A. J. (2004) · Addiction · doi:10.1111/j.1360-0443.2004.00763.x · Cited by 504
O'Malley, S., Krishnan-Sarin, S., Farren, C., Sinha, R., & Kreek, M. (2002) · Psychopharmacology · doi:10.1007/s002130100919 · Cited by 492
Pharmacological Treatment of Alcohol Dependence: A Review of the Evidence
Garbutt, J. C., West, S. L., Carey, T. S., Lohr, K. N., & Crews, F. T. (1999) · JAMA · doi:10.1001/jama.281.14.1318 · Cited by 444
Anton, R. F., Moak, D. H., Waid, L. R., Latham, P. K., Malcolm, R. J., & Dias, J. K. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1758 · Cited by 425
Anticraving Medications for Relapse Prevention: A Possible New Class of Psychoactive Medications
O’Brien, C. P. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.8.1423 · Cited by 405
Efficacy of Naltrexone and Acamprosate for Alcoholism Treatment: A Meta‐Analysis
Kranzler, H. R., & Van Kirk, J. (2001) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2001.tb02356.x · Cited by 390
A comprehensive guide to the application of contingency management procedures in clinical settings
Petry, N. M. (2000) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(99)00071-x · Cited by 381
Pharmacological treatment of alcohol dependence: Target symptoms and target mechanisms
HEILIG, M., & EGLI, M. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.02.001 · Cited by 377
Kreek, M. J., LaForge, K. S., & Butelman, E. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd897 · Cited by 374
Opioid peptides and the control of human ingestive behaviour
Yeomans, M. R., & Gray, R. W. (2002) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(02)00041-6 · Cited by 317
Chick, J. (2000) · Alcohol and Alcoholism · doi:10.1093/alcalc/35.6.587 · Cited by 310
Rösner, S., Leucht, S., Lehert, P., & Soyka, M. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107078308 · Cited by 300
Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis
McPheeters, M., O’Connor, E. A., Riley, S., Kennedy, S. M., Voisin, C., Kuznacic, K., Coffey, C. P., Edlund, M. D., Bobashev, G., & Jonas, D. E. (2023) · JAMA · doi:10.1001/jama.2023.19761 · Cited by 285
A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence
Mason, B. J., Salvato, F. R., Williams, L. D., Ritvo, E. C., & Cutler, R. B. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.8.719 · Cited by 271
Opioid antagonists for alcohol dependence
Srisurapanont, M., & Jarusuraisin, N. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001867.pub2 · Cited by 265
Update on neuropharmacological treatments for alcoholism: Scientific basis and clinical findings
Johnson, B. A. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.08.005 · Cited by 264
Drug therapy for alcohol dependence
Swift, R. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905133401907 · Cited by 255
Streeton, C. (2001) · Alcohol and Alcoholism · doi:10.1093/alcalc/36.6.544 · Cited by 228
Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes
Cramer, J., Rosenheck, R., Kirk, G., Krol, W., & Krystal, J. (2003) · Value in Health · doi:10.1046/j.1524-4733.2003.65269.x · Cited by 212
Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders
Petrakis, I. L., Poling, J., Levinson, C., Nich, C., Carroll, K., & Rounsaville, B. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.02.016 · Cited by 177
Depot naltrexone: long-lasting antagonism of the effects of heroin in humans
Comer, S., Collins, E., Kleber, H., Nuwayser, E., Kerrigan, J., & Fischman, M. (2002) · Psychopharmacology · doi:10.1007/s002130100909 · Cited by 175
The COMBINE Study Research Group (2003) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2003.tb02873.x · Cited by 174
Weerts, E. M., Kim, Y. K., Wand, G. S., Dannals, R. F., Lee, J. S., Frost, J. J., & McCaul, M. E. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301440 · Cited by 147
Drobes, D. J., Anton, R. F., Thomas, S. E., & Voronin, K. (2004) · Alcoholism Clinical and Experimental Research · doi:10.1097/01.alc.0000139704.88862.01 · Cited by 140
Naltrexone and relapse prevention treatment for cocaine-dependent patients
Schmitz, J. M., Stotts, A. L., Rhoades, H. M., & Grabowski, J. (2001) · Addictive Behaviors · doi:10.1016/s0306-4603(00)00098-8 · Cited by 138
Anton, R. F., Drobes, D. J., Voronin, K., Durazo-Avizu, R., & Moak, D. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1720-7 · Cited by 135
Anton, R. F., Moak, D. H., Latham, P., Waid, L. R., Myrick, H., Voronin, K., Thevos, A., Wang, W., & Woolson, R. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000172071.81258.04 · Cited by 121
Pharmacotherapy for alcohol dependence: status of current treatments
Franck, J., & Jayaram-Lindström, N. (2013) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2013.05.005 · Cited by 107
Gabapentin for the treatment of alcohol use disorder
Mason, B. J., Quello, S., & Shadan, F. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1417383 · Cited by 104
Pettinati, H. M., Kampman, K. M., Lynch, K. G., Xie, H., Dackis, C., Rabinowitz, A. R., & O′Brien, C. P. (2008) · Addictive Behaviors · doi:10.1016/j.addbeh.2007.11.011 · Cited by 95
Packages of care for alcohol use disorders in low- and middle-income countries
Benegal, V., Chand, P. K., & Obot, I. S. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000170 · Cited by 94
Developing human laboratory models of smoking lapse behavior for medication screening
McKee, S. A. (2009) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00135.x · Cited by 93
Mason, B. J. (2003) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2003.08.009 · Cited by 75
Intramuscular extended‐release naltrexone: current evidence
Gastfriend, D. R. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05900.x · Cited by 71
Kumar, A., Sharma, A., Bansal, P. D., Bahetra, M., Gill, H. K., & Kumar, R. (2020) · Indian Journal of Psychiatry · doi:10.4103/psychiatry.indianjpsychiatry_201_19 · Cited by 21
Guiraud, J., Addolorato, G., Aubin, H.-J., Batel, P., de Bejczy, A., Caputo, F., Goudriaan, A. E., Gual, A., Lesch, O., Maremmani, I., et al. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.06.003 · Cited by 20
Pharmacotherapy for alcohol use disorder.
Holt, S. R., & Tobin, D. G. (2018) · Medical Clinics of North America · doi:10.1016/j.mcna.2018.02.008 · Cited by 17
Feeney, G. F. X., Connor, J. P., Young, R. M., Tucker, J., & Czajkowski, F. (2001) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2001.00326.x · Cited by 13
(2014) · Työväentutkimus Vuosikirja · Cited by 1
Metadata
- Authors
- Volpicelli, J. R.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 1997-08-01
- Volume
- 54
- Issue
- 8
- Pages
- 737
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2138742021
- Cited by
- 411
- References
- 26
- FWCI
- 15.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.